Cogent Biosciences Inc

NASDAQ COGT

Data sourced from

and

Download Data

Cogent Biosciences Inc Debt to Income Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 20, 2024

Cogent Biosciences Inc Debt to Income Ratio 1 year YoY Change (%) is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The debt to income ratio measures the level of debt relative to a company's net income. It is calculated by dividing total debt by net income. This ratio provides insights into the company's ability to generate sufficient income to cover its debt obligations. A higher ratio indicates a higher level of debt burden relative to the company's income. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: COGT

Cogent Biosciences Inc

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive, Cambridge, MA, United States, 02140
Employees	164
Sector	Healthcare
Industry	Biotechnology

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Key trends